Eintrag weiter verarbeiten
Precision oncology based on omics data: the NCT Heidelberg experience
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 141(2017), 5, Seite 877-886 |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Titel: | Precision oncology based on omics data: the NCT Heidelberg experience/ Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils, Daniela Richter, Katrin Pfütze, Christina Geörg, Bettina Meißburger, Stephan Wolf, Angela Schulz, Roland Penzel, Esther Herpel, Martina Kirchner, Amelie Lier, Volker Endris, Stephan Singer, Peter Schirmacher, Wilko Weichert, Albrecht Stenzinger, Richard F. Schlenk, Evelin Schröck, Benedikt Brors, Christof von Kalle, Hanno Glimm, Stefan Fröhling |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
09 June 2017
|
| Gesamtaufnahme: |
: International journal of cancer, 141(2017), 5, Seite 877-886
, volume:141 |
| Schlagwörter: | |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 07769caa a2201045 4500 | ||
|---|---|---|---|
| 001 | 0-158064645X | ||
| 003 | DE-627 | ||
| 005 | 20220815001344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180904s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.30828 |2 doi | |
| 035 | |a (DE-627)158064645X | ||
| 035 | |a (DE-576)51064645X | ||
| 035 | |a (DE-599)BSZ51064645X | ||
| 035 | |a (OCoLC)1341017993 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Horak, Peter |e VerfasserIn |0 (DE-588)1156426111 |0 (DE-627)1019252839 |0 (DE-576)502179961 |4 aut | |
| 245 | 1 | 0 | |a Precision oncology based on omics data |b the NCT Heidelberg experience |c Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils, Daniela Richter, Katrin Pfütze, Christina Geörg, Bettina Meißburger, Stephan Wolf, Angela Schulz, Roland Penzel, Esther Herpel, Martina Kirchner, Amelie Lier, Volker Endris, Stephan Singer, Peter Schirmacher, Wilko Weichert, Albrecht Stenzinger, Richard F. Schlenk, Evelin Schröck, Benedikt Brors, Christof von Kalle, Hanno Glimm, Stefan Fröhling |
| 264 | 1 | |c 09 June 2017 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.09.2018 | ||
| 520 | |a Precision oncology implies the ability to predict which patients will likely respond to specific cancer therapies based on increasingly accurate, high-resolution molecular diagnostics as well as the functional and mechanistic understanding of individual tumors. While molecular stratification of patients can be achieved through different means, a promising approach is next-generation sequencing of tumor DNA and RNA, which can reveal genomic alterations that have immediate clinical implications. Furthermore, certain genetic alterations are shared across multiple histologic entities, raising the fundamental question of whether tumors should be treated by molecular profile and not tissue of origin. We here describe MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinically applicable platform for prospective, biology-driven stratification of younger adults with advanced-stage cancer across all histologies and patients with rare tumors. We illustrate how a standardized workflow for selection and consenting of patients, sample processing, whole-exome/genome and RNA sequencing, bioinformatic analysis, rigorous validation of potentially actionable findings, and data evaluation by a dedicated molecular tumor board enables categorization of patients into different intervention baskets and formulation of evidence-based recommendations for clinical management. Critical next steps will be to increase the number of patients that can be offered comprehensive molecular analysis through collaborations and partnering, to explore ways in which additional technologies can aid in patient stratification and individualization of treatment, to stimulate clinically guided exploratory research projects, and to gradually move away from assessing the therapeutic activity of targeted interventions on a case-by-case basis toward controlled clinical trials of genomics-guided treatments. | ||
| 650 | 4 | |a clinical trial design | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a precision oncology | |
| 650 | 4 | |a whole-exome sequencing | |
| 700 | 1 | |a Heining, Christoph |e VerfasserIn |0 (DE-588)1156392764 |0 (DE-627)1019233915 |0 (DE-576)502161981 |4 aut | |
| 700 | 1 | |a Gröschel, Stefan |d 1979- |e VerfasserIn |0 (DE-588)138335664 |0 (DE-627)601621565 |0 (DE-576)307122352 |4 aut | |
| 700 | 1 | |a Hutter, Barbara |e VerfasserIn |0 (DE-588)14009752X |0 (DE-627)61602293X |0 (DE-576)314588760 |4 aut | |
| 700 | 1 | |a Fröhlich, Martina |d 1979- |e VerfasserIn |0 (DE-588)1043069305 |0 (DE-627)770092411 |0 (DE-576)39443529X |4 aut | |
| 700 | 1 | |a Hübschmann, Daniel |d 1981- |e VerfasserIn |0 (DE-588)1099133653 |0 (DE-627)858143798 |0 (DE-576)469237082 |4 aut | |
| 700 | 1 | |a Schlesner, Matthias |d 1978- |e VerfasserIn |0 (DE-588)138455201 |0 (DE-627)602593867 |0 (DE-576)307654656 |4 aut | |
| 700 | 1 | |a Eils, Roland |d 1965- |e VerfasserIn |0 (DE-588)1020648287 |0 (DE-627)691291705 |0 (DE-576)361718195 |4 aut | |
| 700 | 1 | |a Richter, Daniela |e VerfasserIn |0 (DE-588)1034764632 |0 (DE-627)746269196 |0 (DE-576)382409329 |4 aut | |
| 700 | 1 | |a Pfütze, Katrin |d 1985- |e VerfasserIn |0 (DE-588)104193565X |0 (DE-627)768025397 |0 (DE-576)393588815 |4 aut | |
| 700 | 1 | |a Geörg, Christina |d 1981- |e VerfasserIn |0 (DE-588)1017957827 |0 (DE-627)690472315 |0 (DE-576)354690892 |4 aut | |
| 700 | 1 | |a Meissburger, Bettina |e VerfasserIn |0 (DE-588)1166164942 |0 (DE-627)1030098743 |0 (DE-576)510651100 |4 aut | |
| 700 | 1 | |a Wolf, Stephan |e VerfasserIn |0 (DE-588)1109104146 |0 (DE-627)864250371 |0 (DE-576)475545141 |4 aut | |
| 700 | 1 | |a Penzel, Roland |e VerfasserIn |0 (DE-588)102044021X |0 (DE-627)691221316 |0 (DE-576)360421083 |4 aut | |
| 700 | 1 | |a Herpel, Esther |d 1973- |e VerfasserIn |0 (DE-588)12965227X |0 (DE-627)476593662 |0 (DE-576)297767984 |4 aut | |
| 700 | 1 | |a Kirchner, Martina |d 1973- |e VerfasserIn |0 (DE-588)1017178976 |0 (DE-627)676266363 |0 (DE-576)353239747 |4 aut | |
| 700 | 1 | |a Lier, Amelie |e VerfasserIn |0 (DE-588)1080501479 |0 (DE-627)844735493 |0 (DE-576)453562841 |4 aut | |
| 700 | 1 | |a Endris, Volker |e VerfasserIn |0 (DE-588)1063753686 |0 (DE-627)812590961 |0 (DE-576)422898198 |4 aut | |
| 700 | 1 | |a Singer, Stephan |d 1974- |e VerfasserIn |0 (DE-588)129891584 |0 (DE-627)483343420 |0 (DE-576)188835482 |4 aut | |
| 700 | 1 | |a Schirmacher, Peter |d 1961- |e VerfasserIn |0 (DE-588)1020440112 |0 (DE-627)691221197 |0 (DE-576)360427448 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 700 | 1 | |a Brors, Benedikt |e VerfasserIn |0 (DE-588)1112102965 |0 (DE-627)866068732 |0 (DE-576)476376157 |4 aut | |
| 700 | 1 | |a Kalle, Christof von |d 1962- |e VerfasserIn |0 (DE-588)1036481115 |0 (DE-627)75107926X |0 (DE-576)168957396 |4 aut | |
| 700 | 1 | |a Glimm, Hanno |d 1967- |e VerfasserIn |0 (DE-588)113880677 |0 (DE-627)51985120X |0 (DE-576)289777879 |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |d 1969- |e VerfasserIn |0 (DE-588)120890046 |0 (DE-627)080950302 |0 (DE-576)188733930 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d Bognor Regis : Wiley-Liss, 1966 |g 141(2017), 5, Seite 877-886 |h Online-Ressource |w (DE-627)269532781 |w (DE-600)1474822-8 |w (DE-576)079876129 |x 1097-0215 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2017 |g number:5 |g pages:877-886 |g extent:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.30828 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.30828 |x Verlag |z kostenfrei |3 Volltext |
| 936 | u | w | |d 141 |j 2017 |e 5 |h 877-886 |g 10 |
| 951 | |a AR | ||
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.30828 |9 LFER |
| 852 | |a LFER |z 2018-09-13T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c Aufsatz | ||
| 935 | |a lfer | ||
| 900 | |a Stenzinger, A. | ||
| 900 | |a Huebschmann, Daniel | ||
| 900 | |a Rütze, Christina | ||
| 900 | |a Meißburger, Bettina | ||
| 900 | |a Gröschel, Stefan Matthias | ||
| 900 | |a Groeschel, Stefan | ||
| 900 | |a Schlenk, Richard F. | ||
| 900 | |a Schlenk, R. F. | ||
| 900 | |a Schlenk, Richard | ||
| 900 | |a Schlesner, Mathias | ||
| 900 | |a Glimm, H. | ||
| 900 | |a Penzel, R. | ||
| 900 | |a Kalle, C. von | ||
| 900 | |a Schirmacher, P. | ||
| 900 | |a Pfutze, Katrin | ||
| 900 | |a Salzmann, Katrin | ||
| 900 | |a Kirchner, M. | ||
| 900 | |a Herpel, E. | ||
| 900 | |a Endris, V. | ||
| 951 | |b XA-DE | ||
| 980 | |a 158064645X |b 0 |k 158064645X |o 51064645X |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Precision+oncology+based+on+omics+data%3A+the+NCT+Heidelberg+experience&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Horak%2C+Peter&rft.pub=&rft.format=Journal&rft.language=English&rft.issn=1097-0215 |
|---|
| _version_ | 1757949945796624384 |
|---|---|
| access_facet | Electronic Resources |
| author | Horak, Peter, Heining, Christoph, Gröschel, Stefan, Hutter, Barbara, Fröhlich, Martina, Hübschmann, Daniel, Schlesner, Matthias, Eils, Roland, Richter, Daniela, Pfütze, Katrin, Geörg, Christina, Meissburger, Bettina, Wolf, Stephan, Penzel, Roland, Herpel, Esther, Kirchner, Martina, Lier, Amelie, Endris, Volker, Singer, Stephan, Schirmacher, Peter, Stenzinger, Albrecht, Schlenk, Richard Friedrich, Brors, Benedikt, Kalle, Christof von, Glimm, Hanno, Fröhling, Stefan |
| author_facet | Horak, Peter, Heining, Christoph, Gröschel, Stefan, Hutter, Barbara, Fröhlich, Martina, Hübschmann, Daniel, Schlesner, Matthias, Eils, Roland, Richter, Daniela, Pfütze, Katrin, Geörg, Christina, Meissburger, Bettina, Wolf, Stephan, Penzel, Roland, Herpel, Esther, Kirchner, Martina, Lier, Amelie, Endris, Volker, Singer, Stephan, Schirmacher, Peter, Stenzinger, Albrecht, Schlenk, Richard Friedrich, Brors, Benedikt, Kalle, Christof von, Glimm, Hanno, Fröhling, Stefan |
| author_role | aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut, aut |
| author_sort | Horak, Peter |
| author_variant | p h ph, c h ch, s g sg, b h bh, m f mf, d h dh, m s ms, r e re, d r dr, k p kp, c g cg, b m bm, s w sw, r p rp, e h eh, m k mk, a l al, v e ve, s s ss, p s ps, a s as, r f s rf rfs, b b bb, c v k cv cvk, h g hg, s f sf |
| callnumber-sort | |
| collection | lfer |
| container_reference | 141(2017), 5, Seite 877-886 |
| container_title | International journal of cancer |
| contents | Precision oncology implies the ability to predict which patients will likely respond to specific cancer therapies based on increasingly accurate, high-resolution molecular diagnostics as well as the functional and mechanistic understanding of individual tumors. While molecular stratification of patients can be achieved through different means, a promising approach is next-generation sequencing of tumor DNA and RNA, which can reveal genomic alterations that have immediate clinical implications. Furthermore, certain genetic alterations are shared across multiple histologic entities, raising the fundamental question of whether tumors should be treated by molecular profile and not tissue of origin. We here describe MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinically applicable platform for prospective, biology-driven stratification of younger adults with advanced-stage cancer across all histologies and patients with rare tumors. We illustrate how a standardized workflow for selection and consenting of patients, sample processing, whole-exome/genome and RNA sequencing, bioinformatic analysis, rigorous validation of potentially actionable findings, and data evaluation by a dedicated molecular tumor board enables categorization of patients into different intervention baskets and formulation of evidence-based recommendations for clinical management. Critical next steps will be to increase the number of patients that can be offered comprehensive molecular analysis through collaborations and partnering, to explore ways in which additional technologies can aid in patient stratification and individualization of treatment, to stimulate clinically guided exploratory research projects, and to gradually move away from assessing the therapeutic activity of targeted interventions on a case-by-case basis toward controlled clinical trials of genomics-guided treatments. |
| ctrlnum | (DE-627)158064645X, (DE-576)51064645X, (DE-599)BSZ51064645X, (OCoLC)1341017993 |
| doi_str_mv | 10.1002/ijc.30828 |
| facet_avail | Online, Free |
| finc_class_facet | not assigned |
| finc_id_str | 0021240348 |
| footnote | Gesehen am 04.09.2018 |
| format | ElectronicBookComponentPart |
| format_access_txtF_mv | Article, E-Article |
| format_de105 | Ebook |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-child |
| format_dezi4 | e-Book |
| format_finc | Article, E-Article |
| format_legacy | ElectronicBookPart |
| format_strict_txtF_mv | E-Article |
| geogr_code | not assigned |
| geogr_code_person | Germany |
| hierarchy_parent_id | 0-269532781 |
| hierarchy_parent_title | International journal of cancer |
| hierarchy_sequence | 141(2017), 5, Seite 877-886 |
| hierarchy_top_id | 0-269532781 |
| hierarchy_top_title | International journal of cancer |
| id | 0-158064645X |
| illustrated | Not Illustrated |
| imprint | 09 June 2017 |
| imprint_str_mv | 09 June 2017 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | 0-158064645X |
| is_hierarchy_title | Precision oncology based on omics data: the NCT Heidelberg experience |
| isil_str_mv | LFER |
| issn | 1097-0215 |
| kxp_id_str | 158064645X |
| language | English |
| last_indexed | 2023-02-16T01:41:51.374Z |
| local_heading_facet_dezwi2 | clinical trial design, next-generation sequencing, personalized medicine, precision oncology, whole-exome sequencing |
| marc024a_ct_mv | 10.1002/ijc.30828 |
| match_str | horak2017precisiononcologybasedonomicsdatathenctheidelbergexperience |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| multipart_link | 079876129 |
| multipart_part | (079876129)141(2017), 5, Seite 877-886 |
| names_id_str_mv | (DE-588)1156426111, (DE-627)1019252839, (DE-576)502179961, (DE-588)1156392764, (DE-627)1019233915, (DE-576)502161981, (DE-588)138335664, (DE-627)601621565, (DE-576)307122352, (DE-588)14009752X, (DE-627)61602293X, (DE-576)314588760, (DE-588)1043069305, (DE-627)770092411, (DE-576)39443529X, (DE-588)1099133653, (DE-627)858143798, (DE-576)469237082, (DE-588)138455201, (DE-627)602593867, (DE-576)307654656, (DE-588)1020648287, (DE-627)691291705, (DE-576)361718195, (DE-588)1034764632, (DE-627)746269196, (DE-576)382409329, (DE-588)104193565X, (DE-627)768025397, (DE-576)393588815, (DE-588)1017957827, (DE-627)690472315, (DE-576)354690892, (DE-588)1166164942, (DE-627)1030098743, (DE-576)510651100, (DE-588)1109104146, (DE-627)864250371, (DE-576)475545141, (DE-588)102044021X, (DE-627)691221316, (DE-576)360421083, (DE-588)12965227X, (DE-627)476593662, (DE-576)297767984, (DE-588)1017178976, (DE-627)676266363, (DE-576)353239747, (DE-588)1080501479, (DE-627)844735493, (DE-576)453562841, (DE-588)1063753686, (DE-627)812590961, (DE-576)422898198, (DE-588)129891584, (DE-627)483343420, (DE-576)188835482, (DE-588)1020440112, (DE-627)691221197, (DE-576)360427448, (DE-588)139606106, (DE-627)703395238, (DE-576)312432755, (DE-588)129025380, (DE-627)387778004, (DE-576)297454102, (DE-588)1112102965, (DE-627)866068732, (DE-576)476376157, (DE-588)1036481115, (DE-627)75107926X, (DE-576)168957396, (DE-588)113880677, (DE-627)51985120X, (DE-576)289777879, (DE-588)120890046, (DE-627)080950302, (DE-576)188733930 |
| oclc_num | 1341017993 |
| physical | 10 |
| publishDate | 09 June 2017 |
| publishDateSort | 2017 |
| publishPlace | |
| publisher | |
| record_format | marcfinc |
| record_id | 51064645X |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Horak, Peter VerfasserIn (DE-588)1156426111 (DE-627)1019252839 (DE-576)502179961 aut, Precision oncology based on omics data the NCT Heidelberg experience Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils, Daniela Richter, Katrin Pfütze, Christina Geörg, Bettina Meißburger, Stephan Wolf, Angela Schulz, Roland Penzel, Esther Herpel, Martina Kirchner, Amelie Lier, Volker Endris, Stephan Singer, Peter Schirmacher, Wilko Weichert, Albrecht Stenzinger, Richard F. Schlenk, Evelin Schröck, Benedikt Brors, Christof von Kalle, Hanno Glimm, Stefan Fröhling, 09 June 2017, 10, Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, Gesehen am 04.09.2018, Precision oncology implies the ability to predict which patients will likely respond to specific cancer therapies based on increasingly accurate, high-resolution molecular diagnostics as well as the functional and mechanistic understanding of individual tumors. While molecular stratification of patients can be achieved through different means, a promising approach is next-generation sequencing of tumor DNA and RNA, which can reveal genomic alterations that have immediate clinical implications. Furthermore, certain genetic alterations are shared across multiple histologic entities, raising the fundamental question of whether tumors should be treated by molecular profile and not tissue of origin. We here describe MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinically applicable platform for prospective, biology-driven stratification of younger adults with advanced-stage cancer across all histologies and patients with rare tumors. We illustrate how a standardized workflow for selection and consenting of patients, sample processing, whole-exome/genome and RNA sequencing, bioinformatic analysis, rigorous validation of potentially actionable findings, and data evaluation by a dedicated molecular tumor board enables categorization of patients into different intervention baskets and formulation of evidence-based recommendations for clinical management. Critical next steps will be to increase the number of patients that can be offered comprehensive molecular analysis through collaborations and partnering, to explore ways in which additional technologies can aid in patient stratification and individualization of treatment, to stimulate clinically guided exploratory research projects, and to gradually move away from assessing the therapeutic activity of targeted interventions on a case-by-case basis toward controlled clinical trials of genomics-guided treatments., clinical trial design, next-generation sequencing, personalized medicine, precision oncology, whole-exome sequencing, Heining, Christoph VerfasserIn (DE-588)1156392764 (DE-627)1019233915 (DE-576)502161981 aut, Gröschel, Stefan 1979- VerfasserIn (DE-588)138335664 (DE-627)601621565 (DE-576)307122352 aut, Hutter, Barbara VerfasserIn (DE-588)14009752X (DE-627)61602293X (DE-576)314588760 aut, Fröhlich, Martina 1979- VerfasserIn (DE-588)1043069305 (DE-627)770092411 (DE-576)39443529X aut, Hübschmann, Daniel 1981- VerfasserIn (DE-588)1099133653 (DE-627)858143798 (DE-576)469237082 aut, Schlesner, Matthias 1978- VerfasserIn (DE-588)138455201 (DE-627)602593867 (DE-576)307654656 aut, Eils, Roland 1965- VerfasserIn (DE-588)1020648287 (DE-627)691291705 (DE-576)361718195 aut, Richter, Daniela VerfasserIn (DE-588)1034764632 (DE-627)746269196 (DE-576)382409329 aut, Pfütze, Katrin 1985- VerfasserIn (DE-588)104193565X (DE-627)768025397 (DE-576)393588815 aut, Geörg, Christina 1981- VerfasserIn (DE-588)1017957827 (DE-627)690472315 (DE-576)354690892 aut, Meissburger, Bettina VerfasserIn (DE-588)1166164942 (DE-627)1030098743 (DE-576)510651100 aut, Wolf, Stephan VerfasserIn (DE-588)1109104146 (DE-627)864250371 (DE-576)475545141 aut, Penzel, Roland VerfasserIn (DE-588)102044021X (DE-627)691221316 (DE-576)360421083 aut, Herpel, Esther 1973- VerfasserIn (DE-588)12965227X (DE-627)476593662 (DE-576)297767984 aut, Kirchner, Martina 1973- VerfasserIn (DE-588)1017178976 (DE-627)676266363 (DE-576)353239747 aut, Lier, Amelie VerfasserIn (DE-588)1080501479 (DE-627)844735493 (DE-576)453562841 aut, Endris, Volker VerfasserIn (DE-588)1063753686 (DE-627)812590961 (DE-576)422898198 aut, Singer, Stephan 1974- VerfasserIn (DE-588)129891584 (DE-627)483343420 (DE-576)188835482 aut, Schirmacher, Peter 1961- VerfasserIn (DE-588)1020440112 (DE-627)691221197 (DE-576)360427448 aut, Stenzinger, Albrecht VerfasserIn (DE-588)139606106 (DE-627)703395238 (DE-576)312432755 aut, Schlenk, Richard Friedrich 1965- VerfasserIn (DE-588)129025380 (DE-627)387778004 (DE-576)297454102 aut, Brors, Benedikt VerfasserIn (DE-588)1112102965 (DE-627)866068732 (DE-576)476376157 aut, Kalle, Christof von 1962- VerfasserIn (DE-588)1036481115 (DE-627)75107926X (DE-576)168957396 aut, Glimm, Hanno 1967- VerfasserIn (DE-588)113880677 (DE-627)51985120X (DE-576)289777879 aut, Fröhling, Stefan 1969- VerfasserIn (DE-588)120890046 (DE-627)080950302 (DE-576)188733930 aut, Enthalten in International journal of cancer Bognor Regis : Wiley-Liss, 1966 141(2017), 5, Seite 877-886 Online-Ressource (DE-627)269532781 (DE-600)1474822-8 (DE-576)079876129 1097-0215 nnns, volume:141 year:2017 number:5 pages:877-886 extent:10, http://dx.doi.org/10.1002/ijc.30828 Verlag Resolving-System kostenfrei Volltext, https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.30828 Verlag kostenfrei Volltext, http://dx.doi.org/10.1002/ijc.30828 LFER, LFER 2018-09-13T00:00:00Z |
| spellingShingle | Horak, Peter, Heining, Christoph, Gröschel, Stefan, Hutter, Barbara, Fröhlich, Martina, Hübschmann, Daniel, Schlesner, Matthias, Eils, Roland, Richter, Daniela, Pfütze, Katrin, Geörg, Christina, Meissburger, Bettina, Wolf, Stephan, Penzel, Roland, Herpel, Esther, Kirchner, Martina, Lier, Amelie, Endris, Volker, Singer, Stephan, Schirmacher, Peter, Stenzinger, Albrecht, Schlenk, Richard Friedrich, Brors, Benedikt, Kalle, Christof von, Glimm, Hanno, Fröhling, Stefan, Precision oncology based on omics data: the NCT Heidelberg experience, Precision oncology implies the ability to predict which patients will likely respond to specific cancer therapies based on increasingly accurate, high-resolution molecular diagnostics as well as the functional and mechanistic understanding of individual tumors. While molecular stratification of patients can be achieved through different means, a promising approach is next-generation sequencing of tumor DNA and RNA, which can reveal genomic alterations that have immediate clinical implications. Furthermore, certain genetic alterations are shared across multiple histologic entities, raising the fundamental question of whether tumors should be treated by molecular profile and not tissue of origin. We here describe MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinically applicable platform for prospective, biology-driven stratification of younger adults with advanced-stage cancer across all histologies and patients with rare tumors. We illustrate how a standardized workflow for selection and consenting of patients, sample processing, whole-exome/genome and RNA sequencing, bioinformatic analysis, rigorous validation of potentially actionable findings, and data evaluation by a dedicated molecular tumor board enables categorization of patients into different intervention baskets and formulation of evidence-based recommendations for clinical management. Critical next steps will be to increase the number of patients that can be offered comprehensive molecular analysis through collaborations and partnering, to explore ways in which additional technologies can aid in patient stratification and individualization of treatment, to stimulate clinically guided exploratory research projects, and to gradually move away from assessing the therapeutic activity of targeted interventions on a case-by-case basis toward controlled clinical trials of genomics-guided treatments., clinical trial design, next-generation sequencing, personalized medicine, precision oncology, whole-exome sequencing |
| swb_id_str | 51064645X |
| title | Precision oncology based on omics data: the NCT Heidelberg experience |
| title_auth | Precision oncology based on omics data the NCT Heidelberg experience |
| title_full | Precision oncology based on omics data the NCT Heidelberg experience Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils, Daniela Richter, Katrin Pfütze, Christina Geörg, Bettina Meißburger, Stephan Wolf, Angela Schulz, Roland Penzel, Esther Herpel, Martina Kirchner, Amelie Lier, Volker Endris, Stephan Singer, Peter Schirmacher, Wilko Weichert, Albrecht Stenzinger, Richard F. Schlenk, Evelin Schröck, Benedikt Brors, Christof von Kalle, Hanno Glimm, Stefan Fröhling |
| title_fullStr | Precision oncology based on omics data the NCT Heidelberg experience Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils, Daniela Richter, Katrin Pfütze, Christina Geörg, Bettina Meißburger, Stephan Wolf, Angela Schulz, Roland Penzel, Esther Herpel, Martina Kirchner, Amelie Lier, Volker Endris, Stephan Singer, Peter Schirmacher, Wilko Weichert, Albrecht Stenzinger, Richard F. Schlenk, Evelin Schröck, Benedikt Brors, Christof von Kalle, Hanno Glimm, Stefan Fröhling |
| title_full_unstemmed | Precision oncology based on omics data the NCT Heidelberg experience Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils, Daniela Richter, Katrin Pfütze, Christina Geörg, Bettina Meißburger, Stephan Wolf, Angela Schulz, Roland Penzel, Esther Herpel, Martina Kirchner, Amelie Lier, Volker Endris, Stephan Singer, Peter Schirmacher, Wilko Weichert, Albrecht Stenzinger, Richard F. Schlenk, Evelin Schröck, Benedikt Brors, Christof von Kalle, Hanno Glimm, Stefan Fröhling |
| title_in_hierarchy | Precision oncology based on omics data: the NCT Heidelberg experience / Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils, Daniela Richter, Katrin Pfütze, Christina Geörg, Bettina Meißburger, Stephan Wolf, Angela Schulz, Roland Penzel, Esther Herpel, Martina Kirchner, Amelie Lier, Volker Endris, Stephan Singer, Peter Schirmacher, Wilko Weichert, Albrecht Stenzinger, Richard F. Schlenk, Evelin Schröck, Benedikt Brors, Christof von Kalle, Hanno Glimm, Stefan Fröhling, |
| title_short | Precision oncology based on omics data |
| title_sort | precision oncology based on omics data the nct heidelberg experience |
| title_sub | the NCT Heidelberg experience |
| topic | clinical trial design, next-generation sequencing, personalized medicine, precision oncology, whole-exome sequencing |
| topic_facet | clinical trial design, next-generation sequencing, personalized medicine, precision oncology, whole-exome sequencing |
| url | http://dx.doi.org/10.1002/ijc.30828, https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.30828 |